Patents Assigned to CONSTELLATION PHARMACEUTICALS, INC.
  • USE OF CBP/EP300 AND BET INHIBITORS FOR TREATMENT OF CANCER
    Publication number: 20170196878
    Abstract: The present invention relates to the use of CBP/EP300 inhibitors and BET inhibitors for the treatment of cancer. In some embodiments, the use is to treat cancer that is resistant to BET inhibitors.
    Type: Application
    Filed: March 20, 2017
    Publication date: July 13, 2017
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Richard C. Centore, Andrew R. Conery, Karen Gascoigne, Robert J. Sims, III
  • Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
    Patent number: 9624244
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: April 18, 2017
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, Victor S. Gehling, Alexander M. Taylor, Rishi G. Vaswani
  • Bromodomain inhibitors and uses thereof
    Patent number: 9522920
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: December 20, 2016
    Assignee: CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Côté, Victor S. Gehling, Jean-Christophe Harmange, Michael Charles Hewitt, Yves Leblanc, Christopher G. Nasveschuk, Alexander M. Taylor, Rishi G. Vaswani
  • Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors
    Patent number: 9505767
    Abstract: The present invention relates to compounds formula (I): and to salts thereof, wherein R1-R4 and A have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of histone demethylases, such as KDM5. Also included are pharmaceutically acceptable compositions comprising the compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: November 29, 2016
    Assignees: Genentech, Inc., Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, Steven F. Bellon, Victor S. Gehling, Jean-Christophe Harmange, Yves LeBlanc, Jun Liang, Steven R. Magnuson, Vickie Hsiao-Wei Tsui, Birong Zhang
  • MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
    Publication number: 20160333016
    Abstract: Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
    Type: Application
    Filed: May 16, 2016
    Publication date: November 17, 2016
    Applicant: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Andrew Cook, Les A. Dakin, Martin Duplessis, Victor S. Gehling, Jean-Christophe Harmange, Christopher G. Nasveschuk, Rishi G. Vaswani
  • Benzo [C] isoxazoloazepine bromodomain inhibitors and uses thereof
    Patent number: 9493483
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: November 15, 2016
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, Michael Charles Hewitt, Victor S. Gehling, Rishi G. Vaswani
  • USE OF CBP/EP300 BROMODOMAIN INHIBITORS FOR CANCER IMMUNOTHERAPY
    Publication number: 20160317632
    Abstract: The present invention relates to use of CBP/EP300 bromodomain inhibitors for the treatment of cancer.
    Type: Application
    Filed: April 11, 2016
    Publication date: November 3, 2016
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, James Edmund Audia, Steven Bellon, Andrea Cochran, Alexandre Cote, Terry Crawford, Benjamin Fauber, Srimoyee Ghosh, Jean-Christophe Harmange, Georgia Hatzivassiliou, Hariharan Jayaram, Jeong Kim, Jose M. Lora, Steven Magnuson, Ira Mellman, Anthony F. Romero, Alexander M. Taylor, Vickie Tsui
  • Modulators of methyl modifying enzymes, compositions and uses thereof
    Patent number: 9469646
    Abstract: Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: October 18, 2016
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Les A. Dakin, Victor S. Gehling, Jean-Christophe Harmange, Christopher G. Nasveschuk, Rishi G. Vaswani
  • Bromodomain inhibitors and uses thereof
    Patent number: 9422292
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: August 23, 2016
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, Victor S. Gehling, Michael Charles Hewitt, Alexander M. Taylor, Jean-Christophe Harmange
  • Modulators of methyl modifying enzymes, compositions and uses thereof
    Patent number: 9409865
    Abstract: Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: August 9, 2016
    Assignee: Constellation_Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Gagnon, Jean-Christophe Harmange, Christopher G. Nasveschuk
  • INDOLE DERIVATIVES AS MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
    Publication number: 20160185757
    Abstract: Agents of formulas (I)/(II)/(III) for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
    Type: Application
    Filed: August 15, 2014
    Publication date: June 30, 2016
    Applicant: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Les A. Dakin, Martin Duplessis, Victor S. Gehling, Jean-Christophe Harmange, Christopher G. Nasveschuk, Rishi G. Vaswani
  • Modulators of methyl modifying enzymes, compositions and uses thereof
    Patent number: 9371331
    Abstract: Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: June 21, 2016
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Andrew S. Cook, Les A. Dakin, Martin Duplessis, Victor S. Gehling, Jean-Christophe Harmange, Christopher G. Nasveschuk, Rishi G. Vaswani
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20160158207
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: November 25, 2015
    Publication date: June 9, 2016
    Applicants: Genentech, Inc., Constellation Pharmaceuticals, Inc.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
  • METHODS OF TREATING CANCER AND PREVENTING CANCER DRUG RESISTANCE
    Publication number: 20160143910
    Abstract: Provided herein are methods of treating and/or preventing cancer drug resistance using antagonists of KDM5.
    Type: Application
    Filed: March 14, 2014
    Publication date: May 26, 2016
    Applicants: CONSTELLATION PHARMACEUTICALS, INC., GENENTECH, INC.
    Inventors: Shilpi Arora, Michael Robert Costa, Ted Lau, Patrick Trojer, Brian K. Albrecht, Shane Buker, Marie Classon, Victor S. Gehling, Jean-Christophe Harmange, Erica L. Jackson, Jun Liang, Heidi Phillips, Peter Sandy, Jeffrey Settleman, Jean-Philippe Stephan
  • Bromodomain inhibitors and uses thereof
    Patent number: 9328117
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: May 3, 2016
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, Jean-Christophe Harmange, Alexandre Cote, Alexander M. Taylor
  • PYRAZOLO COMPOUNDS AND USES THEREOF
    Publication number: 20160060267
    Abstract: Provided are compounds useful as inhibitors of one or more histone demethylases, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using the present composition in the treatment of various disorders.
    Type: Application
    Filed: March 13, 2014
    Publication date: March 3, 2016
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Steven F. Bellon, Victor S. Gehling, Jean-Christophe Harmange, Kwong Wah Lai, Jun Liang, Peter Dragovich, Dan Ortwine, Sharada Labadie, Birong Zhang, Jim Kiefer
  • Bromodomain inhibitors and uses thereof
    Patent number: 9249161
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: February 2, 2016
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Côté, Victor S. Gehling, Jean-Christophe Harmange, Michael Charles Hewitt, Christopher G. Nasveschuk, Alexander M. Taylor, Rishi G. Vaswani
  • TREATING TH2-MEDIATED DISEASES BY INHIBITION OF BROMODOMAINS
    Publication number: 20160024504
    Abstract: The invention provides methods for treating Th2 cytokine-mediated diseases by inhibiting bromodomain function.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Applicants: CONSTELLATION PHARMACEUTICALS, INC., GENENTECH, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Terry Crawford, Benjamin Fauber, Hon-Ren Huang, Jose M. Lora, Steven Magnuson, Christopher G. Nasveschuk, Andres Salmeron, Robert J. Sims, III, Alexander M. Taylor
  • FUSION PROTEINS AND METHODS FOR IDENTIFYING BROMODOMAIN INHIBITING COMPOUNDS
    Publication number: 20160002306
    Abstract: The present invention relates to fusion proteins comprising at least one chromatin binding module and at least one reporter module, wherein a plurality of fusion proteins are capable of forming foci, and associated methods for identifying bromodomain inhibiting compounds.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 7, 2016
    Applicant: CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Hon-Ren Huang, Robert J. Sims, III, Steven Frank Bellon
  • MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
    Publication number: 20150376190
    Abstract: Agents having the structural Formula (II) for modulating histone methyl modifying enzymes, compositions and uses thereof for instance as anti-cancer agents are provided herein.
    Type: Application
    Filed: February 11, 2014
    Publication date: December 31, 2015
    Applicant: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Andrew S. Cook, Les A. Dakin, Martin Duplessis, Victor S. Gehling, Jean-Christophe Harmange, Christopher G. Nasveschuk, Rishi G. Vaswani